Skip Navigation
ChemIDplus Lite•Browse•Advanced

Substance Name: Doxorubicin hydrochloride [USP:JAN]
RN: 25316-40-9
UNII: 82F2G7BL4E
InChIKey: MWWSFMDVAYGXBV-RUELKSSGSA-N

Note

  • Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.

Molecular Formula

  • C27-H29-N-O11.Cl-H

Molecular Weight

  • 579.983
 

Classification Codes

  • Antineoplastic
  • Drug / Therapeutic Agent
  • Human Data
  • Mutation Data
  • Reproductive Effect
  • Tumor Data
* denotes mobile formatted website

Links to Resources

NLM Resources (File Locators)

Regulatory Agencies (Superlist Locators)

Other Resources (Internet Locators)


Search for this InChIKey on the Web

Names and Synonyms

Name of Substance

  • Doxorubicin hydrochloride [USP:JAN]

Synonyms

  • (8S,10S)-10-((3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione hydrochloride
  • ADM hydrochloride
  • Adriacin
  • Adriamycin
  • Adriamycin PFS
  • Adriamycin RDF
  • Adriblastin
  • Adriblastina
  • Adrosal
  • Caelyx
  • CCRIS 740
  • Doxil
  • Doxorubicin HCl
  • Doxorubicin hydrochloride
  • Duxocin
  • EINECS 246-818-3
  • FI 6804
  • Hydroxydaunorubicin hydrochloride
  • KW-125
  • Lipo-Dox
  • Lipodox
  • NSC 123127
  • Rubex
  • UNII-82F2G7BL4E

Systematic Names

  • (8S-cis)-10-((3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxynaphthacene-5,12-dione hydrochloride
  • 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S,10S)-
  • 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxylacetyl)-1-methoxy-, hydrochloride (8S-cis)-
  • Adriamycin hydrochloride

Superlist Name

  • 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)-

Registry Numbers

CAS Registry Number

  • 25316-40-9

FDA UNII

  • 82F2G7BL4E

Related Registry Number

  • 23214-92-8 (Parent)

System Generated Number

  • 0025316409

Molecular Formulas

Molecular Formula

  • C27-H29-N-O11.Cl-H

Molecular Formula Fragments

  • C27-H29-N-O11
  • Cl-H
  • COMPONENT

Structure Descriptors

InChI

InChI=1S/C27H29NO11.ClH/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34;/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3;1H/t10-,13-,15-,17-,22+,27-;/m0./s1

InChIKey

MWWSFMDVAYGXBV-RUELKSSGSA-N

Smiles

Cl.COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO

Toxicity

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
man LDLo intravenous 2571ug/kg/3W- (2.571mg/kg) KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)" Archives of Internal Medicine. Vol. 137, Pg. 385, 1977.
man TDLo intravenous 12mg/kg/26W-I (12mg/kg) CARDIAC: CARDIOMYOPATHY INCLUDING INFARCTION

LUNGS, THORAX, OR RESPIRATION: ACUTE PULMONARY EDEMA		 Annals of Internal Medicine. Vol. 106, Pg. 814, 1987.
mouse LD50 intramuscular 13700ug/kg (13.7mg/kg)   Drugs in Japan Vol. 6, Pg. 506, 1982.
mouse LD50 intraperitoneal 11160ug/kg (11.16mg/kg)   National Cancer Institute Screening Program Data Summary, Developmental Therapeutics Program. Vol. JAN1986,
mouse LD50 intravenous 1245ug/kg (1.245mg/kg)   National Cancer Institute Screening Program Data Summary, Developmental Therapeutics Program. Vol. JAN1986,
mouse LD50 oral 698mg/kg (698mg/kg) SENSE ORGANS AND SPECIAL SENSES: LACRIMATION: EYE

GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"

BEHAVIORAL: MUSCLE WEAKNESS		 Kiso to Rinsho. Clinical Report. Vol. 7, Pg. 1052, 1973.
mouse LD50 subcutaneous 7678ug/kg (7.678mg/kg)   National Cancer Institute Screening Program Data Summary, Developmental Therapeutics Program. Vol. JAN1986,
rabbit LD50 intravenous 5980ug/kg (5.98mg/kg) BEHAVIORAL: MUSCLE WEAKNESS

BEHAVIORAL: FOOD INTAKE (ANIMAL)		 Kiso to Rinsho. Clinical Report. Vol. 7, Pg. 1052, 1973.
rat LD50 intramuscular 16mg/kg (16mg/kg)   Drugs in Japan Vol. 6, Pg. 506, 1982.
rat LD50 intraperitoneal 16030ug/kg (16.03mg/kg) GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"

SKIN AND APPENDAGES (SKIN): "DERMATITIS, ALLERGIC: AFTER TOPICAL EXPOSURE"		 Kiso to Rinsho. Clinical Report. Vol. 7, Pg. 1052, 1973.
rat LD50 intravenous 12510ug/kg (12.51mg/kg)   Kiso to Rinsho. Clinical Report. Vol. 7, Pg. 1052, 1973.
rat LD50 intravenous 12510ug/kg (12.51mg/kg) GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"

SKIN AND APPENDAGES (SKIN): "DERMATITIS, ALLERGIC: AFTER TOPICAL EXPOSURE"		 Kiso to Rinsho. Clinical Report. Vol. 7, Pg. 1052, 1973.
rat LD50 subcutaneous 21840ug/kg (21.84mg/kg) SKIN AND APPENDAGES (SKIN): "DERMATITIS, ALLERGIC: AFTER TOPICAL EXPOSURE"

GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"		 Kiso to Rinsho. Clinical Report. Vol. 7, Pg. 1052, 1973.